Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2023 | Mechanism of action of bitopertin to treat patients with EPP

William Savage • 10 Jun 2023
EHA 2023
Erythropoietic Protoporphyria Rare Diseases Bitopertin

William Savage, MD, PhD, Disc Medicine, Watertown, MA, comments on the mechanism of action of bitopertin, an oral and selective inhibitor of glycine type 1 (GlyT1), which is currently being developed for the treatment of erythropoietic protoporphyria (EPP). This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Employee and stakeholder of Disc Medicine

More from William Savage

0:50
The etiology of erythropoietic protoporphyria
William Savage • 10 Jun 2023
2:50
BEACON trial results: safety & efficacy of bitopertin in adults with EPP
William Savage • 10 Jun 2023

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals